The purpose of this study is to collect clinical data, blood samples, and self reported symptoms of peripheral neuropathy from Chinese patients with breast cancer after treatment with taxanes. This data will be used to develop predictive markers for neuropathy.
Study Type
OBSERVATIONAL
Enrollment
500
FACT-Ntx, EORTC-CIPN20
biomarker analysis
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
RECRUITINGTotal score from the FACT-GOG-Ntx questionnaire
Total score from the FACT-GOG-Ntx questionnaire for peripheral neuropathy, ranging from 0-44,higher value represents a worse outcome
Time frame: Up to 2 years
Predictive value of genetic variants for the development of neuropathy
SNPs related to peripheral neuropathy
Time frame: In the two weeks before start treatment
Total score from the EORTC QLQ - CIPN20 questionnaire
Total score from the EORTC QLQ - CIPN20 questionnaire for peripheral neuropathy, ranging from 20-80,higher value represents a worse outcome
Time frame: Up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.